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Abstract
Objective: Our study aimed to characterize alteration in the immunohistochemical expression of p21 in normal 
tissue of the salivary gland surrounding pleomorphic adenoma, the tumor cells of pleomorphic adenomas, and 
carcinoma arising in pleomorphic adenoma. 
Study design: A selected series of 29 cases of pleomorphic adenomas, and 27 cases of carcinoma ex-pleomorphic 
adenoma (undifferentiated and adenocarcinoma types) were examined. 
Results: The results showed that p21 expression was negative in the most components of normal tissue of the 
salivary gland surrounding pleomorphic adenoma, 24 cases out of 29 of the non tumour duct cells (82.8%), and 
28 (96.6%) cases out of 29 of the acinar cells shows negative p21 expression. P21 expression in pleomorphic ad-
enomas shows that 2 cases out of 29 (6.9%) strongly expressed in the duct cells. p21 was strongly expressed in 
carcinoma cells in 9 (33.3%) cases out of 27. 
Conclusion: Our data suggest that the strong nuclear staining as an indicator for altered p21, then the alteration of 
p21 expression would increase from pleomorphic adenoma to carcinoma arising in pleomorphic adenomas (6.9% 
versus 33.3%).
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Introduction
p21 is a cell cycle regulatory protein encoded by the p21 
WAF 1  gene which is located on chromosome 6p21.2, 
(1-2). It believed that the inhibitory effects on cell divi-
sion by p21 are related to cancerous change of normal 
cells, regulation, cell differentiation and induction of 
apoptosis involving p53 and Rb (3).  P21 plays an impor-
tant role in arresting the cell cycle. Loss of function of 
p21 may favour tumour growth. Pleomorphic salivary 
adenoma (PSA), the most frequent tumour in salivary 
glands, can undergo malignant transformation. Carcino-
ma ex pleomorphic adenoma (CXPA) is more frequent 
in the 5-6th decades of life (4-5). It has been suggested 
that a carcinoma may develop within a recurrent PSA 
or when it remains untreated over an extended period of 
time (6-7). Despite the recognized clinical importance 
of CXPA, little is known about its biology, therefore the 
diagnosis of CXPA is a challenge for pathologists. The 
purpose of this study was to determine, with the use of 
immunohistochemistry, to characterize alteration in the 
immunohistochemical expression of p21 in normal tis-
sue of the salivary gland surrounding pleomorphic ad-
enoma, the tumor cells of pleomorphic adenomas, and 
carcinoma arising in pleomorphic adenoma.  
Materials and Methods
Case selection
A selected series tissue 29 cases of pleomorphic adeno-
mas, and 27 cases of carcinoma ex-pleomorphic adeno-
ma were retrieved from the archive of the oral pathology 
departments in the North West region of England (Table 
1). Normal tissue of the salivary gland surrounding the 
P A 
Cases Age Gender Gland type
CXPA 
Cases Age Gender Gland
Histological sub-
type
Metastasis to 
lymph nodes*
1 87 F Parotid gland 1 77 F Parotid Adenocarcinoma Yes
2 52 M Parotid gland 2 28 M Parotid Adenocarcinoma No
3 63 M Parotid gland 3 78 M Submandibular Undifferentiated Yes
4 48 F Parotid gland 4 45 M Parotid Undifferentiated Yes
5 76 F Parotid gland 5 76 F Parotid Undifferentiated No
6 47 M Parotid gland 6 82 F Parotid Undifferentiated No
7 62 F Parotid gland 7 71 M Parotid Adenocarcinoma No
8 33 M Parotid gland 8 67 M Submandibular Undifferentiated Yes
9 49 F Parotid gland 9 63 M Submandibular Undifferentiated Yes
10 45 M Parotid gland 10 55 M Submandibular Undifferentiated Yes
11 63 F Parotid gland 11 73 M Parotid Undifferentiated Yes
12 53 F Parotid gland 12 71 M Parotid Undifferentiated No
13 27 F Parotid gland 13 64 M Parotid Undifferentiated Yes
14 59 F Parotid gland 14 60 F Parotid Undifferentiated Yes
15 33 F Parotid gland 15 49 F Submandibular Undifferentiated No
16 55 F Parotid gland 16 39 F Parotid Undifferentiated Yes
17 26 F Parotid gland 17 56 M Parotid Undifferentiated No
18 65 F Parotid gland 18 45 F Parotid Undifferentiated Yes
19 40 M Parotid gland 19 57 M Parotid Undifferentiated Yes
20 57 M Parotid gland 20 66 F Parotid Undifferentiated No
21 34 M Parotid gland 21 86 F Submandibular Undifferentiated Yes
22 74 F Parotid gland 22 17 F Parotid Undifferentiated No
23 67 F Parotid gland 23 78 M Submandibular Undifferentiated Yes
24 32 M Parotid gland 24 26 M Parotid Undifferentiated No
25 31 M Parotid gland 25 31 F Parotid Undifferentiated No
26 62 F Parotid gland 26 71 M Parotid Undifferentiated No
27 76 F Parotid gland 27 71 M Parotid Undifferentiated No
28 21 F Parotid gland
29 61 F Parotid gland
Table 1.  Clinical data of 29 pleomorphic adenomas cases (PA) and 27 carcinomas ex-pleomorphic adenomas cases (CXPA).
F: female M: male, * Metastasis to lymph nodes at the time of tumour resection.
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tumour was used as a control in 29 cases of pleomorphic 
adenoma. The immunohistochemical expression of an-
tibodies against p21 was examined in the selected cases. 
The proposed criteria for defining carcinoma ex-pleo-
morphic adenoma by Nagao et al. (8) were used to select 
and reclassify our cases of carcinoma ex-pleomorphic 
adenoma.
The use of strict pathological criteria may underesti-
mate the frequency of carcinoma ex pleomorphic ad-
enoma because the malignant cells in some cases may 
obliterate the original pleomorphic adenoma. 
Inclusion criteria for carcinoma ex-pleomorphic ad-
enoma:
• Major gland primary lesion (parotid or submandibu-
lar)
• Co-existent benign and malignant elements
Benign element can be:
• Pleomorphic adenoma within the tumor mass
• Biopsy proven history of previous PSA (pleomorphic 
salivary adenoma) indicated that it was in the same lo-
cation as the subsequent carcinoma.
Malignant elements can be:
• Undifferentiated carcinoma
• Adenocarcinoma
• Multiple patterns of differentiation including undif-
ferentiated or adenocarcinoma patterns
Exclusion criteria for carcinoma ex-pleomorphic ade-
noma includes any other type of tumor.
All specimens using hematoxylin and eosin slides were 
reviewed by two pathologists to confirm the histopatho-
logical diagnosis and to reclassify the studied cases. The 
carcinoma cases classified according to the above men-
tioned criteria as undifferentiated carcinoma or adeno-
carcinoma. The local NHS Research Ethics Committee 
provided a favourable ethical opinion (Ref: 02/104).
Immunhistochemistry 
Paraffin-embedded, 4-µm-thick tissue sections from all 
56 specimens were cut. The sections were deparaffini-
zed in xylene and rehydrated through graded alcohols. 
Sections were processed used streptavidin-biotin-per-
oxidase method. Briefly, the endogenous peroxidase 
was blocked by 3% hydrogen peroxidase for 5 min fol-
lowed by TBS wash. Nonspecific immunoreactivity 
was blocked by incubation with normal goat serum for 
20 minutes. A purified mouse anti-human monoclonal 
antibody p21 (Pharmingen, San Diego) was diluted to 
10 µ/ml in 20 µ/ml tris buffer saline containing 0.1% 
bovine serum albumin for one hour and fifteen minutes 
at the room temperature. All sections were washed by 
TBS for 5 minutes. Sections were incubated with the 
biotinylated secondary antibody reagent for 30 minutes 
followed by (TBS) wash for 5 minutes. Slides were in-
cubated with streptavidin and horseradish peroxidase 
for 30 minutes followed by (TBS) tris buffer saline 
wash for 5 minutes. Incubate with a prepared chromog-
enic substrate solution (Diaminobenizidine) for 15 min-
utes. Sections were counterstained with 0.25% methyl 
green in distilled water for 5 minutes. Sections were 
dehydrated and mounted in Depax. Squamous cell car-
cinoma was used as positive control. Negative control 
was used only with substitution the primary antibody 
with TBS (Fig. 1a). The percentage of P21 positive nu-
clei was semiquantively assessed by two independent 
observers and scored as: negative (0) no expression of 
nuclear protein, (1) weak staining 0-25% of the total 
cells shows positive staining in the nucleus, (2) moder-
ate staining > 25 – 75% of the total cells in the test area 
show positive nuclear staining, (3) strong staining > 75-
100% cells show positive nuclear staining.
Statistical analysis
Cells of the carcinomatous component of the CXPA 
were always scored. The statistical analysis included the 
use of descriptive statistics; frequencies proportion and 
crossed tabulation. Also, statistical analyses, including 
Mann–Whitney and Wilcoxon’s nonparametric tests, 
were performed on the data. All statistical tests were 
two-sided and p-values less than 0.05 were considered 
to be statistically significant.
Results
p21 expression in the control group (normal tissue) sur-
rounding the pleomorphic adenoma
Of the 29 cases, p21 expression of the non tumour duct 
cells was negative in 24 (82.8%), and weak in 5 cases 
(17.2%) cases with weak staining. P21 (nuclear stain-
ing of the acinar cells) showed negative staining in 28 
(96.6%) cases out of 29, 1 (3.4%) case expressed weak 
staining (Fig. 1b). P21 (nuclear staining in stroma) was 
negative in 29 (100%) cases out of 29. 
P21 expression in pleomorphic adenoma components 
p21 nucleus staining was moderate in tumour duct cells 
in 13 (44.8%) cases out of 29 (Fig. 1c), 13 (44.8%) cases 
showed weak staining (Fig. 1d), 1 (3.4%) case  negative 
staining, and 2 cases  (6.9%) strong staining (Table 2), 
(Fig. 1e). p21 nuclear staining in myxochondroid tissue 
was identified in 20 (69.0%) cases with weak staining, 
4 (13.8%) cases with moderate staining, and 5 (17.2%) 
cases with negative staining (Table 2). Also the cross-
tabulation table showed p21 expression in tumour duct 
cells and myxochondroid tissue (Table 2).
Comparison between staining of different components 
in pleomorphic adenoma and the adjacent tissue around 
this tumour    
Wilcoxon test showed a significant difference (p value 
< 0.001) between p 21 expression in the nuclei of duct 
cells in normal tissue surrounding the tumour and the 
tumour area. The non tumour duct cells showed 24 cases 
with p21 negative staining, whereas there were 5 cases 
with weak staining but in the tumour duct cells, 1 case 
showed negative staining, 13 weak staining, 13 moderate 
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staining, and 2 cases strong staining. We conclude that 
there was a greater alteration of p21 expression in the 
tumour duct cells compared with non tumour duct cells. 
The Wilcoxon test identified a significant difference (p 
value = 0.002) between p21 expression in the nuclear 
staining in myxochondroid and tumour duct cells be-
cause the tumour duct cells showed negative staining in 
1 case, 13 showed weak staining, 13 moderate staining, 
and 2 strong staining but in the myxochondroid tissue, 
5 cases had negative staining, 20 weak staining, and 4 
expressed moderate staining (Table 2). This means that 
the incidence of overexpressed p21 in tumour duct cells 
was higher than in tumour myxochondroid tissue.
p21 expression in carcinoma arising in pleomorphic 
adenoma
1

                               
A B
C
D E
Fig. 1. Showing nuclear staining of p21 in normal tissue of parotid gland and pleomorphic adenoma components (Original mag-
nification x40), A showing p21 negative control, B  showing negative nuclear staining of p21 in ductal and acinar cells in parotid 
gland, C showing moderate nuclear staining of p21 in pleomorphic salivary adenoma, D showing low nuclear staining of p21 in 
pleomorphic salivary adenoma, E strong nuclear staining of p21 in pleomorphic salivary adenoma.
p21 was strongly expressed in carcinoma cells in 9 
(33.3%) cases out of 27 (Fig. 2a). 5 (18.5%) cases showed 
moderate staining (. 2b), and 5 (18.5%) cases expressed 
low staining (Fig. 2c), 8 cases (29.6%) negative staining.
Comparison between p21 expression in pleomorphic 
adenoma and carcinoma arising in pleomorphic ad-
enoma 
The Mann Whitney test showed no significant differ-
ence between p21 expression in pleomorphic adenoma 
(tumour duct cells) and carcinoma arising in PSA (p 
value 0.939 > 0.05). p21 nuclear staining was moder-
ate in tumour duct cells (pleomorphic adenoma ) in 
13 (44.8%) cases out of 29, 13 (44.8%) cases showed 
weak staining, 1 (3.4%) case  negative staining, and 2 
cases  (6.9 %) strong staining but p21 in carcinoma cells 
Med Oral Patol Oral Cir Bucal. 2010 Sep 1;15 (5):e697-703.                                       p21 expression in normal salivary gland, pleomorphic adenoma, and carcinoma ex pleomorphic adenoma
e701
P21 in duct cells
Negative
Staining
Weak 
staining
Moderate 
staining
Strong 
staining Total
P21 expression in Myxochondroid
Negative staining
Weak staining
Moderate staining
Strong staining
Total
0
1
0
0
1
4
7
2
0
13
1
10
2
0
13
0
2
0
0
2
5
20
4
0
29
showed 9 (33,3%) strong staining, 5 cases moderate 
staining (18.5%), 5 cases (18.5%) low staining, 8 cases 
(29.6%) negative staining. These results showed that 
mutation of p21 increased from pleomorphic adenoma 
to carcinoma arising in pleomorphic adenoma.  
Discussion
p21 belongs to a class of tumour suppressors including 
p16 and p27, which control progression through the cell 
cycle by inhibiting the activity of cyclin-cdk complex-
es.
No study has been published regarding p21 expression 
in salivary glands and particularly in carcinoma arising 
in pleomorphic adenoma.
P21 and normal tissue of salivary glands
In the normal salivary glands (control group) p21 was 
negative in the non tumour duct cells or the acini. These 
results are consistent with Rey et al. (9) who studied p21 
expression in breast cancer. The normal ducts and aci-
nar cells did not express p21 and the same negative p21 
nuclear staining was observed in the five non-neoplastic 
cases.  
Clasen et al. (10) analysed the expression of p21 in 
urothelial carcinoma. Their results revealed that no p21 
was expressed in normal mucosa. Jung et al. (11) ana-
lysed the expression of p21 in normal and reactive brain 
in gliomas of various malignancy grades. Immunhisto-
chemical assay showed that the p21 detected in normal 
and reactive brain tissue with at very low expression.
Expression of p21 in the tumour duct cells and myxo-
chondroid tissue in pleomorphic adenomas 
Wilcoxon test showed a significant difference between 
p21 expression of the nuclear staining in myxochon-
droid and tumour duct cells, (p value <0.001).
p21 expression in pleomorphic adenoma showed that 
the incidence of aberrant expression of this protein was 
higher in tumour duct cells than in myxochondroid tis-
sue. Although p21 showed alteration in expression in 
Table 2. Crosstabulation table shows comparison between p21 expression in  myxochondroid tissue and 
tumour duct cells in pleomorphic adenoma.
Fig. 2. Showing nuclear staining of p21 in carcinomas ex-pleomor-
phic adenomas, (Original magnification x40), A showing strong nu-
clear staining of p21 in CXPA. B showing moderate nuclear staining 
of p21 in CXPA, C showing low nuclear staining of p21 in CXPA.
2

A
B
C
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myxochondroid tissue, there is evidence that cells in 
myxochondroid tissue show low levels of proliferation 
Zhu et al. (12).
P21, pleomorphic adenoma, and carcinoma arising in 
pleomorphic  adenoma 
It was considered that p21 strong and moderate nuclear 
staining was positive, and an indicator for altered p21 in 
pleomorphic adenoma and carcinoma arising in PSA. 
Low and negative nuclear staining was classified as 
negative, and indicated wild type (non altered p21). P21 
showed positive nuclear staining (moderate and strong) 
in 15 (51.7%) out of 29 cases in tumour duct cells of ple-
omorphic adenoma. In carcinoma arising in pleomor-
phic adenoma, p21 staining was positive in 14 (51.8%) 
cases out of 27.
De lima et al. (13) reported that no expression of p21 was 
found in adenoid cystic carcinomas. Marques et al. (14) 
reported that p21 expression was considered absent in 
pleomorphic adenomas and myoepitheliomas. Harada 
et al. (3) reported that p21 expression was increased in 
non small lung carcinoma, hepato cellular carcinoma, 
and head and neck cancers. Rey et al. (9) studied p21 
expression in breast cancer. Expression of p21 (using 
anti p21 clone, EA10 from Oncogene Science) was ob-
served in preinvasive lesions, and in infiltrating carci-
nomas (57%). P21 expression was associated with high 
histological grade (II-III). P21 positivity correlated with 
increased proliferation. Jung et al. (11) used an immuno-
histochemical assay and demonstrated that p21 (using 
mAb obtained from Oncogene Science) was positive in 
both astrocytoma (low grade) and glioblastoma (high 
grade) in the tested paraffin blocks of brain tumours. 
Ogawa et al. (15) observed that loss of p21 expression 
correlated with disease progression in gastric carcino-
ma. Brunotto et al. (16) observed that the Ck14, p53, p21 
and Bcl-2 proteins were found modified in the leukopla-
kia, oral lichen planus and squamous cell carcinoma.
P21 strong nuclear staining as a strong indicator for 
altered p21
Using strong nuclear staining as a indicator for altered 
p21, the proportion of p21 positive tissues would be 6.9 
% in pleomorphic adenoma cases. In my sample, only 
2 cases out of 29 showed strong positive staining in the 
tumour duct cells of pleomorphic adenomas. In carci-
noma arising in PSA, 9 (33.3%) cases out of 27 showed 
positive strong staining.
The interpretation of the variations in the detection of 
p21 staining
This differences may have resulted from the following 
reasons:
1. The use of different antibodies
2. Different classifications e.g (0=negative staining, 
1=low, 2= moderate, 3= strong or 0-3= negative and 4= 
positive or 0-2= negative and 3-4=positive or negative 
and positive staining).
3. Fixation times and concentrations of antibodies 
4. The sensitivity of the technique used
Mutation is usually increased as cells progress from 
benign tumour to carcinoma. It was surprising that the 
results showed that the proportion of altered p21 in pleo-
morphic adenomas was comparable with in carcinoma 
cases, 15 (51.7%) out of 29 cases versus 14 (51.8%) cases 
out of 27, after combining moderate and strong stain-
ing together, and negative and low staining together. If 
only strong positive staining (p21) was used as indica-
tor for the alteration in the expression of tumour sup-
pressor protein, then alteration in expression of p21 was 
detected in two cases out of 29 (6.9%) in pleomorphic 
adenoma and increased in carcinoma arising in pleo-
morphic adenoma in nine cases out of 27 (33.3%). 
Immunostaining technique is an easy method to carry 
out but the assessment of the positive or negative nucle-
ar staining cells is controversial. Many authors used dif-
ferent criteria so the results cannot be compared. In the 
present study, the use of negative and positive staining 
for the assessment of staining avoided any confusion in 
the interpretation of the results. Ideally the immunos-
taining technique is used only combined with another 
technique e.g (Ploymerase Chain Reaction, Western 
Blotting) to detect and confirm existence of a mutation. 
Many studies used criteria such as negative, low, moder-
ate, and strong staining. This study comprised 29 cases 
of pleomorphic adenoma and 27 cases of carcinoma ex 
pleomorphic adenoma, although the sample size is lim-
ited but it is bigger compared to other published studies. 
We have concluded that the alteration of p21 expression 
has increased from pleomorphic adenoma to carcinoma 
arising in pleomorphic adenoma depending on use the 
p21 strong nuclear staining as a strong indicator for al-
tered p21.
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